ArticleBMJ oncology2026
Real-world effectiveness of NALIRIFOX versus modified FOLFIRINOX or gemcitabine and nab-paclitaxel in first-line advanced pancreatic adenocarcinoma: a multicentre propensity-matched study.
Tawasapon Thambamroong et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.